Flagyl Er

Pouchitis, Liver Abscess, Amebic, Lung Abscess + 53 more

Treatment

41 FDA approvals

20 Active Studies for Flagyl Er

What is Flagyl Er

Metronidazole

The Generic name of this drug

Treatment Summary

Metronidazole is a type of antibiotic used to treat a range of bacterial and parasitic infections. It is available in several forms, including pills, capsules, topical creams, and suppositories. Metronidazole has been used for many years to treat gastrointestinal infections, trichomoniasis, giardiasis, and amebiasis.

Flagyl

is the brand name

image of different drug pills on a surface

Flagyl Er Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Flagyl

Metronidazole

1963

449

Approved as Treatment by the FDA

Metronidazole, commonly known as Flagyl, is approved by the FDA for 41 uses including Bone and Joint Infections and Abscess .

Bone and Joint Infections

Abscess

Liver Abscess

Communicable Diseases

Osteomyelitis

Bacterial Endocarditis

Helicobacter Pylori Infection

Used to treat Helicobacter Pylori Infection in combination with Bismuth subsalicylate

Abdominal Abscess

Abdominal Infection

Skin and skin structure infections

Gynaecological infection

Lung Abscess

Endometritis

Central Nervous System Bacterial Infections

Bacterial Meningitis

Pneumonia

intra-abdominal bacterial infections

hepatic abscess

Tubo-ovarian abscess

Lung Abscess

Curling Ulcer

Used to treat Duodenal Ulcer in combination with Bismuth subsalicylate

Lower respiratory tract infection bacterial

Bacterial Septicemia

Bacteria, Anaerobic

Bacterial Infections

Duodenal Ulcer

Used to treat Duodenal Ulcer in combination with Bismuth subsalicylate

Meningitis

Abscess, Intra-Abdominal

Empyema

asymptomatic Trichomoniasis

Exposure via partner

Endomyometritis

Bacterial Peritonitis

Central Nervous System Bacterial Infections

Empyema

Trichomonas Infections

Endometritis

Endometritis

Bacteria

Endocarditis, Bacterial

Communicable Diseases

Effectiveness

How Flagyl Er Affects Patients

Metronidazole is used to treat certain infections caused by bacteria and parasites, like amebiasis, trichomoniasis, and giardiasis. It works by damaging the DNA of these microbes, killing them. However, metronidazole is not effective against most other types of bacteria. People taking metronidazole may experience convulsions or numbness of an extremity, so it should be used only when necessary and only for its approved uses. Additionally, it has been found to be carcinogenic in mice and rats, though its effects on humans are unknown.

How Flagyl Er works in the body

Metronidazole is used to fight bacterial and protozoan infections. Researchers aren't sure exactly how it works, but it is thought that the drug enters cells by passive diffusion, and then is changed into toxic metabolites. These metabolites damage the DNA of any replicating organisms, which allows metronidazole to selectively target anaerobic and microaerophilic organisms.

When to interrupt dosage

The amount of Flagyl Er is contingent upon the diagnosed condition, including Exposure by partner, Skin and Curling Ulcer. The dosage fluctuates as per the technique of delivery (e.g. Capsule or Vaginal) outlined in the table below.

Condition

Dosage

Administration

Vulvovaginitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, film coated, Suppository - Rectal, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release, Rectal

Tubo-ovarian abscess

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, film coated, Suppository - Rectal, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release, Rectal

Uterine Cervicitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, film coated, Suppository - Rectal, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release, Rectal

Trichomonas Vaginitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, film coated, Suppository - Rectal, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release, Rectal

Bacterial Vaginosis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, film coated, Suppository - Rectal, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release, Rectal

Pouchitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, film coated, Suppository - Rectal, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release, Rectal

Giardiasis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, film coated, Suppository - Rectal, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release, Rectal

Bacterial Peritonitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, film coated, Suppository - Rectal, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release, Rectal

Vaginitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, film coated, Suppository - Rectal, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release, Rectal

Bacterial Septicemia

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, film coated, Suppository - Rectal, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release, Rectal

Candida albicans

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, film coated, Suppository - Rectal, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release, Rectal

Communicable Diseases

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, film coated, Suppository - Rectal, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release, Rectal

post-surgical vaginal cuff infection

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, film coated, Suppository - Rectal, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release, Rectal

Inflammatory Papule

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, film coated, Suppository - Rectal, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release, Rectal

Exposure via partner

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, film coated, Suppository - Rectal, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release, Rectal

Bacterial Meningitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, film coated, Suppository - Rectal, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release, Rectal

Sinusitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, film coated, Suppository - Rectal, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release, Rectal

Endocarditis, Bacterial

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, film coated, Suppository - Rectal, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release, Rectal

Operative Surgical Procedures

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, film coated, Suppository - Rectal, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release, Rectal

Lockjaw

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Solution - Intravenous, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, film coated, Suppository - Rectal, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Kit - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release, Rectal

Warnings

Flagyl Er has three contraindications, necessitating the abstention from use for the conditions in the subsequent table.

Flagyl Er Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Metronidazole may interact with Pulse Frequency

Pregnancy Trimester, First

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Metronidazole may interact with Pulse Frequency

There are 20 known major drug interactions with Flagyl Er.

Common Flagyl Er Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Metronidazole.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Metronidazole.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Metronidazole.

Alpelisib

Major

The metabolism of Alpelisib can be decreased when combined with Metronidazole.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Metronidazole.

Flagyl Er Toxicity & Overdose Risk

The toxic amount of metronidazole for rats is 5000mg/kg. Taking too much metronidazole can lead to nerve damage, brain toxicity, seizures, sensitivity to alcohol, dark urine, a bad taste in the mouth, nausea, stomach pain, dizziness, and low white blood cells. There is no cure for an overdose of metronidazole. The best treatment is to give the patient activated charcoal and supportive care, and contact the local poison control center for more information.

image of a doctor in a lab doing drug, clinical research

Flagyl Er Novel Uses: Which Conditions Have a Clinical Trial Featuring Flagyl Er?

179 active trials are assessing the potential of Flagyl Er for managing Curling Ulcer, Periodontitis and Central Nervous System Bacterial Infections.

Condition

Clinical Trials

Trial Phases

Lockjaw

0 Actively Recruiting

Uterine Cervical Erosion

0 Actively Recruiting

Gum Disease

2 Actively Recruiting

Not Applicable

Abdominal Infection

0 Actively Recruiting

Rosacea

0 Actively Recruiting

Balantidiasis

0 Actively Recruiting

Empyema

1 Actively Recruiting

Phase 4

Abdominal Abscess

2 Actively Recruiting

Phase 4, Phase 1, Phase 2

Bacteria

0 Actively Recruiting

Trichomonas Infections

0 Actively Recruiting

Vulvovaginitis

0 Actively Recruiting

Lung Abscess

0 Actively Recruiting

Pouchitis

5 Actively Recruiting

Early Phase 1, Phase 4, Phase 2

Atopic Dermatitis

15 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 4, Phase 1

Acne Vulgaris

0 Actively Recruiting

Operative Surgical Procedures

0 Actively Recruiting

Liver Abscess, Amebic

0 Actively Recruiting

Trichomonas Vaginitis

2 Actively Recruiting

Phase 2, Phase 4

Amebic colitis

0 Actively Recruiting

Rosacea

2 Actively Recruiting

Early Phase 1, Phase 2

Flagyl Er Reviews: What are patients saying about Flagyl Er?

5

Patient Review

9/5/2020

Flagyl Er for Vaginosis caused by Bacteria

Even though I was hesitant at first, this medication really worked well for me with no side effects.

5

Patient Review

10/11/2021

Flagyl Er for Infection caused by Bacteroides Fragilis Bacteria

Soon after taking Flagyl, I started feeling drowsy and my thinking slowed down.

5

Patient Review

2/6/2020

Flagyl Er for Diverticulitis

This treatment has been a lifesaver for me. I was diagnosed with IBS over 25 years ago and then Diverticulitis about 15 years ago. Since being put on Flagyl, I haven't had any flare-ups or side effects. It's really amazing and I'm so grateful.

5

Patient Review

2/6/2020

Flagyl Er for Diverticulitis

I've been dealing with IBS and Diverticulitis for a long time, and this is by far the best medication I've tried. No negative side effects that I can tell, and it really helps to take the edge off of my flare-ups.

5

Patient Review

9/5/2020

Flagyl Er for Vaginosis caused by Bacteria

I was hesitant to take this medication because of how severe the potential side effects are, but I'm glad I did. It completely alleviated my symptoms with no negative consequences that I could tell.

5

Patient Review

10/11/2021

Flagyl Er for Infection caused by Bacteroides Fragilis Bacteria

Several hours after taking Flagyl, I felt drowsy and my thinking slowed down.

4.7

Patient Review

4/21/2022

Flagyl Er for Infection caused by Bacteroides Fragilis Bacteria

I've been taking this for my BV and I am noticing a significant difference in my discharge and smell. They're both almost gone! The medicine doesn't taste great or feel good going down, but it is definitely worth it for the results. If you start feeling sick after taking it, don't stop! Just eat a full meal with it, drink lots of water, and avoid sugary or caffeinated drinks. Hopefully it works as well for everyone else as it has for me.

4.7

Patient Review

4/21/2022

Flagyl Er for Infection caused by Bacteroides Fragilis Bacteria

I've been taking this medication for BV and I'm seeing a significant change in my discharge and smell. They're almost gone! This medicine doesn't taste or feel good, but it's worth it for the results. Please don't stop taking this medicine if you feel sick after taking it. Something that helped me was to take it with a full meal, drink lots of water, and avoid sugars and caffeine. Hopefully it works for everyone else as well!

4.3

Patient Review

10/7/2019

Flagyl Er for Vaginosis caused by Bacteria

I was worried about potential side effects but didn't experience any. I also took this treatment with probiotics, as antibiotics can kill all bacteria (good and bad). Was effective.

4.3

Patient Review

10/7/2019

Flagyl Er for Vaginosis caused by Bacteria

I was worried about the potential side effects but thankfully didn't experience any. I also took this medication with probiotics, as antibiotics can kill all bacteria (good and bad). The treatment was effective.

3.7

Patient Review

5/5/2021

Flagyl Er for Infection of a Woman's Reproductive Organs

The medicine got rid of the bv, but I was left feeling nauseous and with an upset stomach until I finished the prescription.

3.7

Patient Review

5/5/2021

Flagyl Er for Infection of a Woman's Reproductive Organs

The medicine cleared up my bacterial vaginosis, but I experienced some intense nausea and stomach discomfort as a result.

2.3

Patient Review

9/24/2020

Flagyl Er for Vaginosis caused by Bacteria

While this drug did get rid of my BV, the side effects were really terrible. I had headaches, hot flashes, chest pain, fatigue, constipation and backaches while taking it. However, it is important to get rid of BV because it can cause major damage if left untreated.

2.3

Patient Review

9/24/2020

Flagyl Er for Vaginosis caused by Bacteria

While this drug did get rid of my BV, the side effects were really terrible. I would not recommend it to anyone unless they are absolutely desperate.

1.3

Patient Review

5/30/2022

Flagyl Er for Infection caused by Bacteroides Fragilis Bacteria

I experienced numbness in my extremities as well as some stomach pain.

1.3

Patient Review

5/30/2022

Flagyl Er for Infection caused by Bacteroides Fragilis Bacteria

I experienced numbness in my extremities as well as stomach pain.

1

Patient Review

7/25/2020

Flagyl Er for infection

This was an awful experience. The first three days I had mild nausea and loss of appetite with a metallic taste. After that it progressed to full-on nausea and vomiting, so I stopped taking the medication after the fourth day.

1

Patient Review

4/13/2022

Flagyl Er for Infection caused by Bacteroides Fragilis Bacteria

Unfortunately, I experienced serious long-term side effects from this medication. 11 months after stopping the treatment, I was left with nerve damage, muscle atrophy and paralysis. Do not take unless you absolutely have to.

1

Patient Review

3/19/2022

Flagyl Er for Diverticulitis

After taking just one pill of this medication, I was vomiting and feeling dizzy for over day and a half.

1

Patient Review

7/14/2022

Flagyl Er for Infection caused by Bacteroides Fragilis Bacteria

Do not take this drug! It made my hands, wrists, arms and ankles immobile. My joints were inflamed and I was in so much pain.

1

Patient Review

7/25/2020

Flagyl Er for infection

This was an awful experience. The first three days I had mild nausea and lost my appetite. Then, it progressed to full-on nausea and vomiting. I stopped after the first dose on the fourth day.

1

Patient Review

8/2/2021

Flagyl Er for Infection caused by Bacteroides Fragilis Bacteria

I absolutely hated this medicine. It tastes terrible, made my stomach hurt, and kept me up at night. I gave up after the fourth day and would never recommend it to anyone.

1

Patient Review

4/13/2022

Flagyl Er for Infection caused by Bacteroides Fragilis Bacteria

Even long after I stopped taking this medication, the nerve damage, muscle atrophy, and paralysis it caused has stayed with me. This ruined my life and should only be taken as a last resort.

1

Patient Review

3/19/2022

Flagyl Er for Diverticulitis

I was incredibly ill after taking just one pill. I suffered from vomiting and dizziness for over 24 hours.

1

Patient Review

7/14/2022

Flagyl Er for Infection caused by Bacteroides Fragilis Bacteria

I would not recommend this drug to anyone. It caused immense pain and inflammation in my joints, making it difficult to move my arms or legs.

1

Patient Review

8/2/2021

Flagyl Er for Infection caused by Bacteroides Fragilis Bacteria

I really disliked this medicine. It left a terrible taste in my mouth and gave me an upset stomach. I couldn't sleep, so I stopped taking it after the fourth day.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about flagyl er

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Flagyl ER used for?

"Flagyl ER is a prescription medicine used to treat the symptoms of bacterial infections. It may be used alone or with other medications. Flagyl ER belongs to a class of drugs called Nitroimidazoles."

Answered by AI

What is extended-release Flagyl?

"To reduce the development of drug-resistant bacteria, Flagyl ER should only be used to treat or prevent infections that are proven or strongly suspected to be caused by bacteria."

Answered by AI

What is the difference between Flagyl and Flagyl er?

"Flagyl Injection is an intravenous form of the drug.

The three drugs Flagyl, Flagyl ER, and Flagyl Injection all contain the active ingredient metronidazole, which is an antimicrobial drug used to treat various bacterial infections. Flagyl is the regular form of metronidazole, while Flagyl ER is an extended-release formula. Flagyl Injection is an intravenous form of the drug."

Answered by AI

Is Flagyl ER still available?

"If you're looking for Flagyl ER, there are generic equivalents available that have been approved by the FDA."

Answered by AI

Clinical Trials for Flagyl Er

Image of Boise VA Medical Center in Boise, United States.

Pharmacist-Led E-Consults for Lung Health in HIV

18+
All Sexes
Boise, ID

People with HIV (PWH) continue to experience elevated risk of community-acquired pneumonia despite effective antiretroviral therapy. Pneumonia contributes to hospitalization, respiratory failure, cardiovascular complications, long-term decline in lung function, and mortality. Several modifiable factors increase this risk, including active smoking, inadequate receipt of respiratory vaccinations, and inappropriate or prolonged use of inhaled corticosteroids (ICS) or proton-pump inhibitors (PPIs). OPTIMIZE Lung-HIV is a multicenter, patient-level randomized controlled hybrid Type 1 effectiveness-implementation trial evaluating whether a proactive, pharmacist-led E-consult intervention can improve evidence-based pulmonary pharmacotherapy for PWH. Pharmacists will review electronic health records, generate tailored recommendations, and pre-enter orders related to smoking cessation pharmacotherapy, vaccinations, and deprescribing of ICS or PPIs. Providers may enact or modify recommendations as clinically appropriate. The trial will assess the proportion of recommendations enacted within 3 months (primary outcome) and at 12 months (maintenance) and will use mixed methods guided by CFIR and RE-AIM to evaluate adoption, feasibility, acceptability, and implementation barriers and facilitators.

Waitlist Available
Has No Placebo

Boise VA Medical Center (+2 Sites)

Kristina A. Crothers, MD

Have you considered Flagyl Er clinical trials?

We made a collection of clinical trials featuring Flagyl Er, we think they might fit your search criteria.
Go to Trials
Image of Corvus Clinical Trials in South San Francisco, United States.

Soquelitinib for Eczema

18+
All Sexes
South San Francisco, CA

The main purpose of this study is to see how well different doses of soquelitinib work in participants with atopic dermatitis (AD) as compared to a placebo (pill with no medicine in it). To check this, the study doctors will examine participants' skin regularly to track how their AD changes during the study. The study doctors will see how safe soquelitinib is by tracking side effects among participants. They will also check "tolerability," which means how well the participants can handle soquelitinib and whether any potential side effects are manageable for them. To understand how well soquelitinib works, it will be compared with a placebo. Placebo is a substance that looks like soquelitinib but contains no active medicine in it. Participants will: * Take study treatment (soquelitinib or placebo) every day for 12 weeks * Visit the clinic for check-ups and tests every week for the first 2 weeks then every 2 weeks during the treatment period, and then return for follow-up visits 30, 60, and 90 days after the last dose of study treatment

Phase 2
Recruiting

Corvus Clinical Trials

Isin Sinem Bagci, MD

Corvus Pharmaceuticals, Inc.

Image of ALS Global in Irving, United States.

GX-03 for Eczema

18 - 70
All Sexes
Irving, TX

This is a randomized, double-blind, vehicle-controlled clinical study designed to evaluate the efficacy and safety of GX-03, a topically applied emollient, in adult subjects with moderate to severe eczema. Approximately 120 adult participants will be enrolled and randomized in a 1:1 ratio to receive either GX-03 or a petrolatum-based vehicle control for 8 consecutive weeks. Efficacy will be assessed using validated clinical outcome measures, including the Eczema Area and Severity Index (EASI), the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™), and the Peak Pruritus Numeric Rating Scale (PP-NRS). Safety will be evaluated through monitoring of treatment-emergent adverse events throughout the study period.

Phase 2
Recruiting

ALS Global

Turn Therapeutics

Image of Seeding Labs INC in Austin, United States.

Tailored Recommendations for Infant Gut Microbiome

No minimum age - 3
All Sexes
Austin, TX

The goal of this clinical trial is to learn whether microbiome analysis, education, and personalized recommendations can improve gut health and reduce early markers of immune-related conditions in infants aged 0-3 months delivered via Cesarean section. The study aims to determine whether these interventions can increase beneficial bacteria, decrease C-section-associated microbiome signatures, reduce opportunistic pathogens, and improve functional potential for HMO digestion and SCFA production. The study also seeks to assess whether improvements in microbiome composition are associated with a reduced prevalence of early atopic symptoms. Researchers will compare three groups: a full intervention arm that receives microbiome reports, coaching, personalized recommendations, and educational materials; a limited intervention arm that receives simplified reports and basic recommendations; and a control arm that receives no results until study completion. This design allows evaluation of both a comprehensive intervention and a more scalable, minimal-results model. Participants will: 1. Provide six microbiome stool samples over a 24-month period. 2. Provide additional small stool samples at two timepoints for exploratory metabolomic analysis. 3. Receive microbiome reports and guidance according to their assigned study arm. 4. Complete surveys on infant health history, symptoms, diet, and environmental exposures. 5. Participate in standardized eczema assessment(s) administered by a Nurse Practitioner and evaluated by a Pediatric Allergy Specialist if any symptoms are reported. This study seeks to demonstrate that targeted microbiome support can positively shift gut microbial development in C-section infants and may reduce risks linked to the early stages of the atopic march. Findings may inform scalable strategies for delivering microbiome-based support in early life and improve long-term health outcomes for this high-risk population.

Recruiting
Has No Placebo

Seeding Labs INC

Qian Yuan, MD

Seeding, Inc DBA Tiny Health

Image of Children's of Alabama in Birmingham, United States.

Antibiotic Duration for Infections in Children

60 - 17
All Sexes
Birmingham, AL

Infections like pneumonia, skin and soft tissue infection (also called SSTI or cellulitis), and urinary tract infections (UTI) are some of the most common reasons children get admitted to the hospital. All three of these conditions require antibiotics for treatment. Although antibiotics are needed to treat the infection and help children feel better, taking them longer than needed can negatively impact children and their families. Negative impacts include things like the burdens of taking more medications and medication side effects. There are guidelines (instructions) from expert medical organizations that suggest the number of days children need antibiotics, but they give a wide range (between 5 and 14 days). Unfortunately, these guidelines are not based on high-quality studies. National data suggests that doctors often choose on the higher end of this range when writing prescriptions for children in the hospital. Our three caregiver co-investigators, other parents of hospitalized children, doctors, other care providers, and researchers, all believe that additional study is needed to determine the best length of antibiotic treatment that weighs both the benefits and harms of antibiotics. The goal of our study is to understand if 5 total days of antibiotic treatment compared to 10 total days of antibiotic treatment is better for children who have been in the hospital for pneumonia, SSTI, or UTI. We will study this question through a randomized control trial. In other words, half of the children will receive 5-days of antibiotics and the other half will receive 10-days of antibiotics. Children in this study (and their caregivers) will not know how many days of antibiotics they will receive to cure their infection because some children will take a placebo (or a pill without antibiotics in it). Only the pharmacy will know if a child is getting antibiotic or placebo (for days 6-10 of treatment). During the first phase of the trial (feasibility phase), 4 hospitals will enroll children in the study. We plan on enrolling 50 patients during this phase. We are starting with just 4 hospitals, so our study team can create and update our study plans if needed. We will closely review information about how many patients and families agree to participate, and if they have any trouble completing any part of the study. We will also interview families to understand the choice to participate in the study, the choice not to participate in the study, and what it is like to be in the study. During the second study phase, we will enroll 1150 more patients across all 11 hospitals. Families will complete short, daily surveys until the 15th day after they started antibiotics, then a larger survey at day 15, at day 20, and at day 30. These surveys will ask about the child's symptoms and recovery from their illness, how the antibiotics are making them feel, and if they had to go back to their doctor, emergency room, or hospital. The answers to these questions will be combined to measure how well the child did, balancing feeling better and having bad effects from the antibiotics. We will use mathematical tests to determine which antibiotic duration is better for treating these illnesses. We will complete other mathematical tests to see if all children should receive the same length of antibiotics or if certain children should be prescribed shorter courses and others longer courses.

Phase 4
Waitlist Available

Children's of Alabama (+9 Sites)

Sunitha V Kaiser, MD, MSc

Have you considered Flagyl Er clinical trials?

We made a collection of clinical trials featuring Flagyl Er, we think they might fit your search criteria.
Go to Trials

Have you considered Flagyl Er clinical trials?

We made a collection of clinical trials featuring Flagyl Er, we think they might fit your search criteria.
Go to Trials